4-pregenen-11β-17-21-triol-3,20-dione derivatives
AssigneeAllergan, Inc.
InventorsJeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
Claims12
A method of treating a disorder associated with glucocorticoid receptor modulation, which comprises administering to a patient an ophthalmically acceptable pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
Dependencies are inferred from the claim text.